BioCentury
ARTICLE | Clinical News

PulmoXen: Phase I data

April 14, 2014 7:00 AM UTC

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the tria...